Literature DB >> 30008086

The neural γ2α1β2α1β2 gamma amino butyric acid ion channel receptor: structural analysis of the effects of the ivermectin molecule and disulfide bridges.

Meral Ayan1, Sebnem Essiz2.   

Abstract

While ~30% of the human genome encodes membrane proteins, only a handful of structures of membrane proteins have been resolved to high resolution. Here, we studied the structure of a member of the Cys-loop ligand gated ion channel protein superfamily of receptors, human type A γ2α1β2α1β2 gamma amino butyric acid receptor complex in a lipid bilayer environment. Studying the correlation between the structure and function of the gamma amino butyric acid receptor may enhance our understanding of the molecular basis of ion channel dysfunctions linked with epilepsy, ataxia, migraine, schizophrenia and other neurodegenerative diseases. The structure of human γ2α1β2α1β2 has been modeled based on the X-ray structure of the Caenorhabditis elegans glutamate-gated chloride channel via homology modeling. The template provided the first inhibitory channel structure for the Cys-loop superfamily of ligand-gated ion channels. The only available template structure before this glutamate-gated chloride channel was a cation selective channel which had very low sequence identity with gamma aminobutyric acid receptor. Here, our aim was to study the effect of structural corrections originating from modeling on a more reliable template structure. The homology model was analyzed for structural properties via a 100 ns molecular dynamics (MD) study. Due to the structural shifts and the removal of an open channel potentiator molecule, ivermectin, from the template structure, helical packing changes were observed in the transmembrane segment. Namely removal of ivermectin molecule caused a closure around the Leu 9 position along the ion channel. In terms of the structural shifts, there are three potential disulfide bridges between the M1 and M3 helices of the γ2 and 2 α1 subunits in the model. The effect of these disulfide bridges was investigated via monitoring the differences in root mean square fluctuations (RMSF) of individual amino acids and principal component analysis of the MD trajectory of the two homology models-one with the disulfide bridge and one with protonated Cys residues. In all subunit types, RMSF of the transmembrane domain helices are reduced in the presence of disulfide bridges. Additionally, loop A, loop F and loop C fluctuations were affected in the extracellular domain. In cross-correlation analysis of the trajectory, the two model structures displayed different coupling in between the M2-M3 linker region, protruding from the membrane, and the β1-β2/D loop and cys-loop regions in the extracellular domain. Correlations of the C loop, which collapses directly over the bound ligand molecule, were also affected by differences in the packing of transmembrane helices. Finally, more localized correlations were observed in the transmembrane helices when disulfide bridges were present in the model. The differences observed in this study suggest that dynamic coupling at the interface of extracellular and ion channel domains differs from the coupling introduced by disulfide bridges in the transmembrane region. We hope that this hypothesis will be tested experimentally in the near future.

Entities:  

Keywords:  Allosteric proteins; Conformational dynamics; Homology modeling; Ligand gated ion channel proteins; Neural GABA type A receptor; Neurotransmitters

Mesh:

Substances:

Year:  2018        PMID: 30008086     DOI: 10.1007/s00894-018-3739-z

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  57 in total

1.  Exploring the essential collective dynamics of interacting proteins: application to prion protein dimers.

Authors:  Bilkiss B Issack; Mark Berjanskii; David S Wishart; Maria Stepanova
Journal:  Proteins       Date:  2012-05-10

2.  Identification of a possible secondary picrotoxin-binding site on the GABA(A) receptor.

Authors:  Timothy S Carpenter; Edmond Y Lau; Felice C Lightstone
Journal:  Chem Res Toxicol       Date:  2013-10-02       Impact factor: 3.739

3.  Protein structure modeling with MODELLER.

Authors:  Narayanan Eswar; David Eramian; Ben Webb; Min-Yi Shen; Andrej Sali
Journal:  Methods Mol Biol       Date:  2008

4.  HOLE: a program for the analysis of the pore dimensions of ion channel structural models.

Authors:  O S Smart; J G Neduvelil; X Wang; B A Wallace; M S Sansom
Journal:  J Mol Graph       Date:  1996-12

Review 5.  Atomic structure and dynamics of pentameric ligand-gated ion channels: new insight from bacterial homologues.

Authors:  Pierre-Jean Corringer; Marc Baaden; Nicolas Bocquet; Marc Delarue; Virginie Dufresne; Hugues Nury; Marie Prevost; Catherine Van Renterghem
Journal:  J Physiol       Date:  2009-12-07       Impact factor: 5.182

6.  The role of conserved leucines in the M2 domain of the acetylcholine receptor in channel gating.

Authors:  G N Filatov; M M White
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

7.  Stabilization of the GluCl ligand-gated ion channel in the presence and absence of ivermectin.

Authors:  Ozge Yoluk; Torben Brömstrup; Edward J Bertaccini; James R Trudell; Erik Lindahl
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

8.  Crystal structure of Lymnaea stagnalis AChBP complexed with the potent nAChR antagonist DHβE suggests a unique mode of antagonism.

Authors:  Azadeh Shahsavar; Jette S Kastrup; Elsebet Ø Nielsen; Jesper L Kristensen; Michael Gajhede; Thomas Balle
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

9.  Functional characterization of ivermectin binding sites in α1β2γ2L GABA(A) receptors.

Authors:  Argel Estrada-Mondragon; Joseph W Lynch
Journal:  Front Mol Neurosci       Date:  2015-09-25       Impact factor: 5.639

10.  X-ray structure of the human α4β2 nicotinic receptor.

Authors:  Claudio L Morales-Perez; Colleen M Noviello; Ryan E Hibbs
Journal:  Nature       Date:  2016-10-03       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.